Vivek Ramaswamy’s Net Worth Has Nearly Doubled While He’s Running For Ohio Governor

Key Concepts

• Vivek Ramaswami's Net Worth Growth: Significant increase in net worth while running for Ohio governor.
• Roy Vance Sciences: Ramaswami's former pharmaceutical company, a primary driver of his wealth.
• Drug Revitalization Strategy: Roy Vance's business model of developing abandoned drugs.
• Spin-offs and Acquisitions: Key events involving subsidiaries like Accident, Telivant, and GOIX.
• Capital Gains: Significant income declared from selling company shares.
• Strive Asset Management: Ramaswami's "anti-woke" firm that transitioned to a Bitcoin treasury company.
• Chapter: A startup co-founded by Ramaswami assisting seniors with Medicare.
• Gubernatorial Campaign Funding: Ramaswami's campaign finances compared to his opponent.

Vivek Ramaswami's Financial Surge Amidst Gubernatorial Campaign

Vivek Ramaswami's net worth has seen a substantial increase, nearly doubling to approximately $1.88 billion, an 80% surge in just nine months, while he is actively campaigning for Ohio governor. This financial growth occurred after his 2024 presidential campaign loss and his departure from Doge in January 2025. He announced his bid for governor in February, expressing optimism about a "new golden age in America" and aiming to position Ohio as a leader in "capitalism and meritocracy."

Roy Vance Sciences: The Engine of Wealth Growth

The primary catalyst for Ramaswami's net worth surge is his former pharmaceutical company, Roy Vance Sciences, which he founded in 2014. The company's strategy focused on revitalizing abandoned drug candidates.

• Accident Spin-off: An early spin-off, Accident, went public in 2015 with a $3 billion valuation. However, its stock plummeted after an Alzheimer's drug trial failed in 2017. Ramaswami reportedly retained his Accident stock.
• Early Share Sales and Capital Gains: Ramaswami sold some Roy Vance shares early, declaring $37 million in capital gains in 2015, citing being "forced to sell" for a new investor.
• Strategic Sales and Valuations:
  • In 2019, Roy Vance sold five subsidiaries and a 10% stake to Sumitomo for $3 billion, valuing the company at $9 billion. This transaction resulted in Ramaswami declaring over $170 million in capital gains on his 2020 tax returns.
  • Two of Sumitomo's top-selling drugs in North America, GOIX (for prostate cancer) and Gemtessa (for overactive bladders), originated from Roy Vance.
• Company Evolution and Exit: Ramaswami transitioned from CEO to chairman of Roy Vance in 2021. The company subsequently went public via a SPAC merger. In early 2023, he left the board to pursue the US presidency.
• Telivant Sale: In October 2023, Roy Vance sold another spin-off, Telivant, to Swiss pharma company RO for $7.1 billion, leading to a 34% stock increase for Telivant by year-end.
• Recent Drug Trial Success: In September of the current year, Roy Vance Sciences' stock surged 72% following positive phase 3 trial results for a drug targeting an autoimmune disease causing muscle weakness and skin lesions.

Despite his departure from the company, Ramaswami's stake of approximately 49 million shares in Roy Vance Sciences is now valued at over $1 billion, with an additional $210 million from stock options. A spokesperson for Ramaswami confirmed Forbes's figures as "broadly correct."

Other Investments and Ventures

Ramaswami's wealth portfolio extends beyond Roy Vance Sciences:

• Chapter: He holds a $100 million (6.7%) stake in Chapter, a startup he co-founded in 2020 that assists seniors with Medicare navigation. Chapter was valued at $1.5 billion after a $75 million Series D funding round in April.
• Strive Asset Management: His "anti-woke" firm, founded in 2022, transitioned into a Bitcoin treasury company this year. Strive's share price experienced a 74% drop following mergers with asset entities and a second planned merger due to unfavorable investor terms. However, his stake, previously valued at $150 million, appears stable despite the decline.
• Buzzfeed: Ramaswami also holds a small investment in the media company Buzzfeed.

Gubernatorial Campaign Funding

Ramaswami's campaign for Ohio governor is well-funded, having raised $9.7 million by the end of July, according to reports filed with the Ohio Secretary of State. This significantly outpaces the $1.4 million raised by his leading Democratic opponent, physician Amy Acton. In contrast to his presidential bid, where he personally contributed $26 million, Ramaswami has only loaned his current campaign approximately $200,000, a small fraction of his overall wealth.

Conclusion

Vivek Ramaswami has experienced a remarkable financial ascent, largely driven by the success of his former pharmaceutical company, Roy Vance Sciences, and its strategic spin-offs and sales. This wealth accumulation has continued even as he has transitioned into politics, with his current gubernatorial campaign being substantially funded by external contributions rather than personal investment, a notable shift from his previous presidential run. His diverse investment portfolio, including stakes in Chapter and Strive Asset Management, further solidifies his financial standing.